light chain amyloidosis

E852351

Light chain amyloidosis is a rare systemic disorder in which misfolded immunoglobulin light chains form amyloid deposits in organs such as the heart and kidneys, leading to progressive organ dysfunction.

All labels observed (2)

Label Occurrences
light chain (AL) amyloidosis 1
light chain amyloidosis canonical 1

How this entity was disambiguated

Statements (64)

Predicate Object
instanceOf immunoglobulin light chain deposition disease ⓘ
plasma cell dyscrasia ⓘ
protein misfolding disease ⓘ
rare disease ⓘ
systemic amyloidosis ⓘ
affectsOrgan autonomic nervous system ⓘ
bone marrow ⓘ
gastrointestinal tract ⓘ
heart ⓘ
kidneys ⓘ
liver ⓘ
peripheral nerves ⓘ
soft tissues ⓘ
hasAbbreviation AL amyloidosis ⓘ
hasAssociation monoclonal gammopathy of undetermined significance ⓘ
multiple myeloma ⓘ
hasBiomarker abnormal serum free light chain ratio ⓘ
monoclonal light chain in serum or urine ⓘ
hasCause clonal plasma cell disorder ⓘ
misfolded immunoglobulin light chains ⓘ
monoclonal gammopathy ⓘ
hasClinicalFeature arrhythmias ⓘ
constipation ⓘ
diarrhea ⓘ
fatigue ⓘ
heart failure with preserved ejection fraction ⓘ
hepatomegaly ⓘ
macroglossia ⓘ
malabsorption ⓘ
nephrotic syndrome ⓘ
orthostatic hypotension ⓘ
periorbital purpura ⓘ
peripheral neuropathy ⓘ
proteinuria ⓘ
restrictive cardiomyopathy ⓘ
weight loss ⓘ
hasDiagnosticTest 99mTc‑pyrophosphate or DPD scintigraphy to differentiate from ATTR amyloidosis ⓘ
bone marrow biopsy ⓘ
cardiac MRI ⓘ
echocardiography ⓘ
immunohistochemistry for light chains ⓘ
mass spectrometry typing of amyloid ⓘ
serum and urine protein electrophoresis ⓘ
serum free light chain assay ⓘ
tissue biopsy with Congo red staining ⓘ
hasEpidemiology more common in older adults ⓘ
rare disorder with incidence of a few cases per million per year ⓘ
hasGoalOfTherapy hematologic complete response ⓘ
organ response ⓘ
hasOutcome high mortality without treatment ⓘ
progressive organ dysfunction ⓘ
hasPathophysiology amyloid fibril deposition in tissues ⓘ
organ infiltration by amyloid ⓘ
toxic effects of circulating light chains ⓘ
hasPrognosticFactor baseline cardiac biomarkers ⓘ
cardiac involvement ⓘ
difference between involved and uninvolved free light chains ⓘ
hasTreatment bortezomib-based chemotherapy ⓘ
cyclophosphamide-bortezomib-dexamethasone regimen ⓘ
daratumumab-based regimens ⓘ
high-dose melphalan with autologous stem cell transplant ⓘ
renal replacement therapy in kidney failure ⓘ
supportive heart failure therapy ⓘ
isPreventedBy no established primary prevention ⓘ

How these facts were elicited

Referenced by (2)

Full triples — surface form annotated when it differs from this entity's canonical label.

CD38 → therapeuticArea → light chain amyloidosis ⓘ
daratumumab → indicatedFor → light chain (AL) amyloidosis ⓘ
linked to: light chain amyloidosis